Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idronoxil Combined With Radiation in Metastatic Prostate Cancer
NCT03041285Phase 1Terminated
- Sponsor
- Royal North Shore Hospital
- Start
- Aug 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of idronoxil in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Royal North Shore Hospital. Primary endpoint: Safety of Idronoxil dose escalation. Started Aug 2017; status: terminated.
02
Drugs
idronoxil
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03041285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041285.